LONDON (ShareCast) - (Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.
In a brief statement, the company noted the volatility in its share price following the recently-announced licensing and development agreement with US speciality pharmaceutical group Avion - which will see Avion will fund an international phase III trial for its lead programme, Lupuzor - and speculation about a possible fundraising.

"The board can confirm that the company is adequately funded and has no intention of raising funds," it said.

At 1510 GMT, the shares were up 1.5% at 18.02p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE